Business
Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Covid-19 Inflammatory Cytokine Storm Treatment
Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Covid-19 Inflammatory Cytokine Storm Treatment.
About this update from Halberd Corp.
[{"type":"text","content":"JACKSON CENTER, PA / ACCESSWIRE / April 12, 2021 / Halberd Corporation (OTC PINK:HALB) filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, "Covid-19 Inflammatory Cytokine Storm Treatment." The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously.William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, "We sought patent protection beyond the U.S. through the PCT process, thus we are able to protect our technology in many countries across the globe. Halberd's patented extracorporeal treatment process opens the door to treatment of Covid-19 and other diseases through radiofrequency elimination (experimentation already underway simultaneously with GreenBioAZ and Youngstown State University). Laser ablation methodologies are also being explored currently with a European technology source, but are considered a bigger technology hurdle due to the requirement for high-speed computer targeting required for the laser.The Halberd U.S. provisional patent application "Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients" was initially filed with the U.S. Patent and Trademark Office on April 8, 2020. Halberd holds exclusive worldwide license to this technology.To get the latest news on Halberd's exciting developments, subscribe by submitting this form.(https://halberdcorporation.com/contact-us/)For more information please contact:William A. [email protected];[email protected]://www.halberdcorporation.comTwitter:@HalberdCAbout Halberd Corporation.Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending COVID-19 extracorporeal treatments:Title Patent/ Application No. Filing DateStatus/Document*Method for Treating and Curing Covid-19 InfectionUS 62/98998103/16/2020Provisionalprovisional_COVID-19_kk,4823-1130-2071.docxPCT/US21/2254103/16/2021International PCT995-004PCT-Application-FINAL.pdf*Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Mor...